HK1205941A1 - Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate - Google Patents
Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate Download PDFInfo
- Publication number
- HK1205941A1 HK1205941A1 HK15106555.7A HK15106555A HK1205941A1 HK 1205941 A1 HK1205941 A1 HK 1205941A1 HK 15106555 A HK15106555 A HK 15106555A HK 1205941 A1 HK1205941 A1 HK 1205941A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- laquinimod
- multiple sclerosis
- combination
- dmf
- presenting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Exchange Systems With Centralized Control (AREA)
- Liquid Crystal Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616337P | 2012-03-27 | 2012-03-27 | |
| US61/616,337 | 2012-03-27 | ||
| US13/800,047 US20130259856A1 (en) | 2012-03-27 | 2013-03-13 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
| US13/800,047 | 2013-03-13 | ||
| PCT/US2013/033885 WO2013148690A1 (en) | 2012-03-27 | 2013-03-26 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1205941A1 true HK1205941A1 (en) | 2015-12-31 |
Family
ID=49235339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15106555.7A HK1205941A1 (en) | 2012-03-27 | 2013-03-26 | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US20130259856A1 (enExample) |
| EP (1) | EP2830623A4 (enExample) |
| JP (2) | JP2015512406A (enExample) |
| KR (1) | KR20150003765A (enExample) |
| CN (2) | CN105853422A (enExample) |
| AR (1) | AR090491A1 (enExample) |
| AU (2) | AU2013239850A1 (enExample) |
| CA (1) | CA2868259A1 (enExample) |
| EA (1) | EA201491773A1 (enExample) |
| HK (1) | HK1205941A1 (enExample) |
| IL (1) | IL234687A0 (enExample) |
| MX (1) | MX2014011616A (enExample) |
| SG (2) | SG11201405755QA (enExample) |
| TW (1) | TW201343164A (enExample) |
| UY (1) | UY34720A (enExample) |
| WO (1) | WO2013148690A1 (enExample) |
| ZA (1) | ZA201407722B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2334378T3 (da) | 2008-08-19 | 2014-07-07 | Xenoport Inc | Prodrugs af methylhydrogenfumarat, farmaceutiske sammensætninger deraf og fremgangsmåder til anvendelse |
| CA2851525A1 (en) | 2011-10-12 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with combination of laquinimod and fingolimod |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| WO2013116657A1 (en) | 2012-02-03 | 2013-08-08 | Teva Pharmaceutical Industries Ltd. | USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNFα THERAPY |
| AR090073A1 (es) | 2012-02-16 | 2014-10-15 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos |
| TW201400117A (zh) | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| EP2692343A1 (en) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Combination therapy for treatment of multiple sclerosis |
| TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| US20140348915A9 (en) | 2012-08-22 | 2014-11-27 | Xenoport, Inc. | Oral Dosage Forms of Methyl Hydrogen Fumarate and Prodrugs Thereof |
| JP2015527372A (ja) | 2012-08-22 | 2015-09-17 | ゼノポート，インコーポレイティド | 副作用を低減させるモノメチルフマレートおよびそのプロドラッグの投与方法 |
| MX2015005632A (es) | 2012-11-07 | 2016-02-05 | Teva Pharma | Sales de amina de laquinimod. |
| CA2901849A1 (en) | 2013-03-14 | 2014-09-25 | Teva Pharmaceutical Industries Ltd. | Crystals of laquinimod sodium and improved process for the manufacture thereof |
| US10179118B2 (en) | 2013-03-24 | 2019-01-15 | Arbor Pharmaceuticals, Llc | Pharmaceutical compositions of dimethyl fumarate |
| US9302977B2 (en) | 2013-06-07 | 2016-04-05 | Xenoport, Inc. | Method of making monomethyl fumarate |
| WO2014205392A1 (en) | 2013-06-21 | 2014-12-24 | Xenoport, Inc. | Cocrystals of dimethyl fumarate |
| US9416096B2 (en) | 2013-09-06 | 2016-08-16 | Xenoport, Inc. | Crystalline forms of (N,N-Diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate, methods of synthesis and use |
| US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
| EP3110408B1 (en) | 2014-02-28 | 2019-01-16 | Banner Life Sciences LLC | Controlled release enteric soft capsules of fumarate esters |
| US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
| US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
| US9999672B2 (en) | 2014-03-24 | 2018-06-19 | Xenoport, Inc. | Pharmaceutical compositions of fumaric acid esters |
| WO2015168103A1 (en) | 2014-04-29 | 2015-11-05 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (rrms) patients with a high disability status |
| EP3256125B1 (en) | 2014-12-11 | 2022-01-26 | Actelion Pharmaceuticals Ltd | Dosing regimen for ponesimod, a selective s1p1 receptor agonist |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| GB2540163A (en) * | 2015-07-07 | 2017-01-11 | Univ London Queen Mary | Combination therapy for treating multiple sclerosis |
| WO2017120355A1 (en) * | 2016-01-06 | 2017-07-13 | Teva Pharmaceutical Industries Ltd. | Dihydroquinolines and uses thereof |
| WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
| US12483171B2 (en) | 2023-12-18 | 2025-11-25 | Abb Schweiz Ag | Plug and play solid state controller for high efficiency motors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6077851A (en) | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
| SE0400235D0 (sv) | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
| EP1915387B1 (en) * | 2005-07-07 | 2010-01-20 | Aditech Pharma AG | Novel glucopyranose esters and glucofuranose esters of alkyl- fumarates and their pharmaceutical use |
| EP2687512A1 (en) | 2005-10-19 | 2014-01-22 | Teva Pharmaceutical Industries Ltd. | Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof |
| AU2007258366B2 (en) | 2006-06-12 | 2012-10-25 | Active Biotech, Ab | Stable laquinimod preparations |
| LT2139467T (lt) * | 2007-02-08 | 2016-10-10 | Biogen Ma Inc. | Neuroapsauga, sergant demielinizuojančia liga |
| WO2008097596A2 (en) * | 2007-02-08 | 2008-08-14 | Biogen Idec Ma Inc. | Nrf2 screening assays and related methods and compositions |
| US20100260755A1 (en) * | 2009-04-09 | 2010-10-14 | Medicinova, Inc. | Ibudilast and immunomodulators combination |
| CN102427727A (zh) * | 2009-04-29 | 2012-04-25 | 比奥根艾迪克Ma公司 | 神经变性和神经炎症的治疗 |
| WO2010147665A1 (en) * | 2009-06-19 | 2010-12-23 | Teva Pharmaceutical Industries Ltd. | Treatment of multiple sclerosis with laquinimod |
| PT2533634E (pt) * | 2010-02-12 | 2015-12-28 | Biogen Ma Inc | Neuroproteção em doenças desmielinizantes |
| RU2603047C2 (ru) * | 2011-01-25 | 2016-11-20 | Новартис Аг | Система и способы для медицинского использования отображения и захвата движения |
| TW201347762A (zh) * | 2012-05-02 | 2013-12-01 | Teva Pharma | 高劑量拉喹莫德（ｌａｑｕｉｎｉｍｏｄ）於治療多發性硬化症之用途 |
-
2013
- 2013-03-13 US US13/800,047 patent/US20130259856A1/en not_active Abandoned
- 2013-03-25 AR ARP130100966 patent/AR090491A1/es unknown
- 2013-03-25 TW TW102110549A patent/TW201343164A/zh unknown
- 2013-03-26 CN CN201610252021.1A patent/CN105853422A/zh active Pending
- 2013-03-26 EP EP13768294.4A patent/EP2830623A4/en not_active Withdrawn
- 2013-03-26 CN CN201380016933.3A patent/CN104470520A/zh active Pending
- 2013-03-26 CA CA 2868259 patent/CA2868259A1/en not_active Abandoned
- 2013-03-26 SG SG11201405755QA patent/SG11201405755QA/en unknown
- 2013-03-26 SG SG10201607976WA patent/SG10201607976WA/en unknown
- 2013-03-26 EA EA201491773A patent/EA201491773A1/ru unknown
- 2013-03-26 MX MX2014011616A patent/MX2014011616A/es unknown
- 2013-03-26 JP JP2015503465A patent/JP2015512406A/ja not_active Withdrawn
- 2013-03-26 KR KR20147030064A patent/KR20150003765A/ko not_active Withdrawn
- 2013-03-26 AU AU2013239850A patent/AU2013239850A1/en not_active Abandoned
- 2013-03-26 HK HK15106555.7A patent/HK1205941A1/xx unknown
- 2013-03-26 WO PCT/US2013/033885 patent/WO2013148690A1/en not_active Ceased
- 2013-04-02 UY UY34720A patent/UY34720A/es not_active Application Discontinuation
-
2014
- 2014-09-16 IL IL234687A patent/IL234687A0/en unknown
- 2014-10-23 ZA ZA2014/07722A patent/ZA201407722B/en unknown
-
2015
- 2015-01-05 US US14/589,684 patent/US20150119420A1/en not_active Abandoned
- 2015-09-14 US US14/853,826 patent/US20160000774A1/en not_active Abandoned
-
2017
- 2017-04-24 US US15/495,406 patent/US20170224675A1/en not_active Abandoned
- 2017-05-26 JP JP2017104051A patent/JP2017200927A/ja not_active Withdrawn
- 2017-07-27 US US15/662,165 patent/US20170319570A1/en not_active Abandoned
- 2017-11-03 US US15/803,017 patent/US20180050031A1/en not_active Abandoned
-
2018
- 2018-01-04 AU AU2018200065A patent/AU2018200065A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20180050031A1 (en) | 2018-02-22 |
| US20130259856A1 (en) | 2013-10-03 |
| SG11201405755QA (en) | 2014-10-30 |
| SG10201607976WA (en) | 2016-11-29 |
| EP2830623A4 (en) | 2015-09-02 |
| IL234687A0 (en) | 2014-11-30 |
| JP2017200927A (ja) | 2017-11-09 |
| CA2868259A1 (en) | 2013-10-03 |
| ZA201407722B (en) | 2016-06-29 |
| EA201491773A1 (ru) | 2015-02-27 |
| AU2018200065A1 (en) | 2018-02-01 |
| MX2014011616A (es) | 2014-10-17 |
| EP2830623A1 (en) | 2015-02-04 |
| AU2013239850A1 (en) | 2014-11-06 |
| WO2013148690A1 (en) | 2013-10-03 |
| KR20150003765A (ko) | 2015-01-09 |
| CN105853422A (zh) | 2016-08-17 |
| AR090491A1 (es) | 2014-11-19 |
| US20170224675A1 (en) | 2017-08-10 |
| US20160000774A1 (en) | 2016-01-07 |
| US20170319570A1 (en) | 2017-11-09 |
| JP2015512406A (ja) | 2015-04-27 |
| CN104470520A (zh) | 2015-03-25 |
| UY34720A (es) | 2013-10-31 |
| US20150119420A1 (en) | 2015-04-30 |
| TW201343164A (zh) | 2013-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
| HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
| HK1198279A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate | |
| HK1198278A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta | |
| HK1203356A1 (en) | Pharmaceutical combinations comprising a thionucleotide analog | |
| WO2015095811A8 (en) | Combination therapy with neoantigen vaccine | |
| IN2015DN03219A (enExample) | ||
| WO2013188847A8 (en) | Compositions and methods for transmucosal absorption | |
| WO2014052935A3 (en) | Combination of rasagiline and pridopidine for treating neurodegenerative disorders, in particular huntington's disease | |
| HK1209672A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fampridine | |
| HK1218251A1 (zh) | 用拉喹莫德治疗多发性硬化症 | |
| HK1218865A1 (zh) | 用於降低多发性硬化症中丘脑损伤的拉喹莫德 | |
| GB2497453B (en) | Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV | |
| HK1223855A1 (zh) | 拉喹莫德和氟吡汀组合物用於治疗多发性硬化症 | |
| WO2013038200A3 (en) | Neurodevelopmental disorders | |
| WO2013074050A3 (en) | Magnetic diffusional patch | |
| HK1208356A1 (en) | Methods of maintaining, treating or improving cognitive function | |
| PT2686005T (pt) | Composições tópicas compreendendo diamina oxidase para o tratamento ou prevenção de doenças associadas com elevados níveis de histamina que envolvem um aumento na dor | |
| PH12014500252A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate | |
| HK1227691A1 (zh) | 利用拉喹莫德和特立氟胺的组合来治疗多发性硬化症 | |
| WO2015065628A3 (en) | Laquinimod combination therapy for treatment of multiple sclerosis | |
| WO2014170820A3 (en) | A pharmaceutical combination for treating tuberculosis | |
| HK1223854A1 (zh) | 通过阿仑单抗诱导随後通过拉喹莫德疗法来治疗多发性硬化症 | |
| AR088093A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y acetato de glatiramer | |
| HK1207008A1 (en) | Use of thymosin alpha for treatment of purulent rhinosinusitis |